NEUROCRINE BIOSCIENCES Clinical Trials

Company details

Status: Public
HQ: 6027 Edgewood Bend Ct, San Diego, California 92130, US
Founded: 1992
Employees: 2,307
Programs: 79
Drugs: 28
Patents: 111

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

Neurocrine Biosciences pipeline update: what analysts should watch next Jun 8, 2026

View all news & analysis →

Recent trial activity

8 updates

Latest clinical program signals indexed for NEUROCRINE BIOSCIENCES.

Trial registry

122 studies

2023-508305-24-00
NBI-1076986-1761

Phase 1 active other

Movement disorders

CTIS ↗
2023-508433-14-00
NBI-98854-ATS3019

Phase 3 active small_molecule

Schizophrenia

CTIS ↗
2023-508814-40-00
NBI-1117570-1769

Phase 1 active other

Neurological and neuropsychiatric conditions

CTIS ↗
2023-509170-33-00
NBI-74788-CAH2006

Phase 3 active small_molecule

Classic Congenital Adrenal Hyperplasia (CAH)

CTIS ↗
2023-509171-16-00
NBI-74788-CAH3003

Phase 3 active small_molecule

Classic Congenital Adrenal Hyperplasia (CAH)

CTIS ↗
2024-514127-42-00
NBI-74788

Phase 2 active small_molecule

Congenital adrenal hyperplasia (CAH)

CTIS ↗
2024-519418-29-00
NBI-1065845-MDD3024

Phase 3 active small_molecule

Major Depressive Disorder

CTIS ↗
2024-519420-25-00
NBI-1065845-MDD3025

Phase 3 active small_molecule

Major Depressive Disorder

CTIS ↗
2024-519421-37-00
NBI-1065845-MDD3026

Phase 3 active small_molecule

Major Depressive Disorder

CTIS ↗
2024-519423-24-00
NBI-1065845

Phase 3 active small_molecule

Major Depressive Disorder

CTIS ↗
2025-520541-72-00
NBI-1065845-MDD3027

Phase 3 active small_molecule

Major Depressive Disorder

CTIS ↗
2025-521215-39-00
NBI-1117568-SCZ3030

Phase 3 active small_molecule

Schizophrenia

CTIS ↗
2025-521216-19-00
NBI-1117568, NBI-1117568

Phase 3 active small_molecule

Schizophrenia, Schizophrenia

CTIS ↗
2025-521868-35-00
NBI-1117570-SCZ2035

Phase 2 active small_molecule

Schizophrenia

CTIS ↗
2025-524134-26-00
Effect of NBI-921355 on corticospinal excitability in healthy participants

Phase 1 active other

Epilepsy

CTIS ↗
NCT00014677
interleukin-4 PE38KDEL cytotoxin

Phase 2 completed mab

Brain and Central Nervous System Tumors

CT.gov ↗
NCT00039052
interleukin-4 PE38KDEL cytotoxin

Phase 1 completed mab

Breast Cancer

CT.gov ↗
NCT00079495
NBI-5788

Phase 2 completed small_molecule

Multiple Sclerosis

CT.gov ↗
NCT00232167
Indiplon

Phase 3 terminated small_molecule

Insomnia

CT.gov ↗
NCT00519818
Chronocort®

Phase 3 completed small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT00525941
NBI-34060

Phase 3 terminated small_molecule

Insomnia

CT.gov ↗
NCT00873561
NBI-6024

Phase 1 completed small_molecule

Type 1 Diabetes Mellitus

CT.gov ↗
NCT01267188
NBI-98854

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT01393600
NBI-98854

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT01403038
Elagolix

Phase 1 completed small_molecule

Folliculogenesis

CT.gov ↗
NCT01688037
NBI-98854

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT01733121
NBI-98854

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT01735617
Hydrocortisone Modified Release Capsules

Phase 2 completed small_molecule

Endocrine Disease

CT.gov ↗
NCT01910480
NBI-98854 50 mg capsule once daily

Phase 1 completed small_molecule

Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

CT.gov ↗
NCT01916993
NBI-98854 50 mg capsule

Phase 1 completed small_molecule

Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects

CT.gov ↗
NCT01960530
Hydrocortisone granules

Phase 1 completed small_molecule

Adrenal Insufficiency

CT.gov ↗
NCT01973543
VY-AADC01

Phase 1 completed mab

Parkinson's Disease

CT.gov ↗
NCT02256475
NBI-98854

Phase 2 terminated small_molecule

Tourette Syndrome

CT.gov ↗
NCT02274558
NBI-98854

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT02349503
NBI-77860

Phase 1 terminated small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT02405091
NBI-98854

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT02408068
Dexamethasone

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT02561156
TAK-653 Placebo

Phase 1 completed small_molecule

Depressive Disorder

CT.gov ↗
NCT02566759
TAK-831 Oral Suspension

Phase 1 terminated small_molecule

Schizophrenia, Cerebellar Ataxia

CT.gov ↗
NCT02581865
NBI-98854

Phase 2 terminated small_molecule

Tourette Syndrome

CT.gov ↗
NCT02679079
NBI-98854

Phase 2 terminated small_molecule

Tourette Syndrome

CT.gov ↗
NCT02716818
Chronocort®

Phase 3 completed small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT02716987
TAK-831

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT02720952
Infacort®

Phase 3 completed small_molecule

Adrenal Insufficiency

CT.gov ↗
NCT02733367
Infacort®

Phase 3 completed small_molecule

Adrenal Insufficiency

CT.gov ↗
NCT02736955
Valbenazine

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT02748694
TAK-041

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT02777268
Infacort

Phase 1 completed small_molecule

Healthy Subjects

CT.gov ↗
NCT02879578
Valbenazine

Phase 2 completed small_molecule

Tourette Syndrome

CT.gov ↗
NCT02959892
Amphetamine

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT02966652
DITEST

Phase 1 completed small_molecule

Male Hypogonadism

CT.gov ↗
NCT03019614
Hydrocortisone

Phase 3 completed small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT03051893
Chronocort

Phase 1 completed small_molecule

Adrenal Insufficiency

CT.gov ↗
NCT03062280
Hydrocortisone

Phase 3 completed small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT03065192
VY-AADC01

Phase 1 completed small_molecule

Idiopathic Parkinson's Disease

CT.gov ↗
NCT03101293
TAK-831

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT03178214
Infacort®

Phase 3 completed small_molecule

Adrenal Insufficiency

CT.gov ↗
NCT03214588
TAK-831

Phase 2 completed small_molecule

Friedreich Ataxia

CT.gov ↗
NCT03224325
TAK-831 Tablet T2

Phase 1 completed small_molecule

Healthy

CT.gov ↗
NCT03311932
Infacort®

Phase 3 completed small_molecule

Adrenal Insufficiency

CT.gov ↗
NCT03319953
TAK-041

Phase 2 completed small_molecule

Stable Schizophrenia

CT.gov ↗
NCT03325010
Valbenazine

Phase 2 completed small_molecule

Tourette Syndrome

CT.gov ↗
NCT03343327
Chronocort

Phase 1 completed small_molecule

Adrenal Insufficiency

CT.gov ↗
NCT03359785
Luvadaxistat

Phase 2 completed small_molecule

Schizophrenia

CT.gov ↗
NCT03382639
Luvadaxistat

Phase 2 completed small_molecule

Schizophrenia

CT.gov ↗
NCT03444038
Valbenazine

Phase 2 completed small_molecule

Tourette Syndrome

CT.gov ↗
NCT03496870
Opicapone

Phase 1 completed small_molecule

Parkinson Disease

CT.gov ↗
NCT03525886
NBI-74788

Phase 2 completed small_molecule

CAH - Congenital Adrenal Hyperplasia

CT.gov ↗
NCT03530293
Valbenazine

Phase 2 completed small_molecule

Tourette Syndrome

CT.gov ↗
NCT03532022
Chronocort®

Phase 3 completed small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT03562494
VY-AADC02

Phase 1 completed mab

Parkinson's Disease

CT.gov ↗
NCT03687684
TAK-831

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT03698331
Valbenazine

Approved completed small_molecule

Tardive Dyskinesia (TD)

CT.gov ↗
NCT03706469
TAK-831 T2

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT03732534
NBI-98854

Phase 2 terminated small_molecule

Tourette Syndrome

CT.gov ↗
NCT03792672
TAK-653

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT03891862
Valbenazine

Approved completed small_molecule

Tardive Dyskinesia (TD)

CT.gov ↗
NCT04045145
Crinecerfont

Phase 2 completed small_molecule

CAH - Congenital Adrenal Hyperplasia

CT.gov ↗
NCT04102579
Valbenazine

Phase 3 active small_molecule

Chorea, Huntington

CT.gov ↗
NCT04234672
TAK-831 Oral Tablet

Phase 1 completed small_molecule

Healthy Volunteers

CT.gov ↗
NCT04400331
Valbenazine

Phase 3 active small_molecule

Chorea, Huntington

CT.gov ↗
NCT04490915
Crinecerfont

Phase 3 active small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT04625101
NBI-827104

Phase 2 terminated small_molecule

Epileptic Encephalopathy

CT.gov ↗
NCT04806451
Crinecerfont

Phase 3 active small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT04873869
NBI-921352

Phase 2 active small_molecule

SCN8A Developmental and Epileptic Encephalopathy Syndrome

CT.gov ↗
NCT04880616
NBI-827104

Phase 2 completed small_molecule

Essential Tremor

CT.gov ↗
NCT05053321
Valbenazine

Phase 3 completed small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT05063994
Chronocort®

Phase 3 completed small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT05110157
Placebo

Phase 3 completed small_molecule

Schizophrenia

CT.gov ↗
NCT05159908
NBI-921352

Phase 2 completed small_molecule

Focal Onset Seizure

CT.gov ↗
NCT05165394
Placebo

Phase 2 completed small_molecule

Anhedonia

CT.gov ↗
NCT05182476
Placebo

Phase 3 completed small_molecule

Schizophrenia

CT.gov ↗
NCT05203341
Placebo

Phase 2 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT05206513
Placebo

Phase 3 completed small_molecule

Dyskinesia

CT.gov ↗
NCT05207085
Valbenazine Oral Capsule

Phase 2 active small_molecule

Trichotillomania (Hair-Pulling Disorder)

CT.gov ↗
NCT05222152
Chronocort

Phase 2 completed small_molecule

Primary Adrenal Insufficiency

CT.gov ↗
NCT05226780
NBI-921352

Phase 2 active small_molecule

SCN8A Developmental and Epileptic Encephalopathy Syndrome

CT.gov ↗
NCT05299554
Chronocort®

Phase 3 completed small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT05301894
NBI-827104

Phase 2 terminated small_molecule

Epileptic Encephalopathy

CT.gov ↗
NCT05493293
NBI-921352

Phase 2 completed small_molecule

Focal Onset Seizure

CT.gov ↗
NCT05545111
NBI-1117568

Phase 3 active small_molecule

Schizophrenia

CT.gov ↗
NCT05654870
Valbenazine

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT05859698
Valbenazine

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT06107829
Valbenazine Oral Capsule

Approved terminated small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT06267846
NBI-1070770

Phase 2 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT06312189
Valbenazine

Phase 3 active small_molecule

Chorea, Huntington

CT.gov ↗
NCT06786624
NBI-1065845

Phase 3 active small_molecule

Major Depressive Disorder

CT.gov ↗
NCT06911112
NBI-1065845

Phase 3 active small_molecule

Major Depressive Disorder

CT.gov ↗
NCT06963021
NBI-1065845

Phase 3 active small_molecule

Major Depressive Disorder

CT.gov ↗
NCT06963034
NBI-1117568

Phase 3 active small_molecule

Schizophrenia

CT.gov ↗
NCT06966401
NBI-1065845

Phase 3 active small_molecule

Major Depressive Disorder

CT.gov ↗
NCT07105098
NBI-1117568

Phase 3 active small_molecule

Schizophrenia

CT.gov ↗
NCT07105111
Valbenazine

Approved active small_molecule

Schizophrenia

CT.gov ↗
NCT07111988
Valbenazine

Phase 2 active small_molecule

Obsessive-Compulsive Disorder

CT.gov ↗
NCT07114874
NBI-1117568

Phase 3 active small_molecule

Schizophrenia

CT.gov ↗
NCT07187375
Crinecerfont

Phase 3 active small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗
NCT07196501
NBI-1065845

Phase 3 active small_molecule

Major Depressive Disorder

CT.gov ↗
NCT07227818
NBI-1117568

Phase 3 active small_molecule

Schizophrenia

CT.gov ↗
NCT07288320
NBI-1117568

Phase 2 active small_molecule

Bipolar I Disorder

CT.gov ↗
NCT07288333
NBI-1117570

Phase 2 active small_molecule

Schizophrenia

CT.gov ↗
NCT07365462
NBI-1065890

Phase 2 active small_molecule

Tardive Dyskinesia

CT.gov ↗
NCT07536269
Crinecerfont

Phase 3 active small_molecule

Congenital Adrenal Hyperplasia

CT.gov ↗